港股異動 | 平安好醫生三連升創16個月新高 股價有望衝擊歷史新高
格隆匯10月10日丨平安好醫生(1833.HK)近日股價重啟升勢,三個交易日累升近12%創16個月新高,股價有望衝擊歷史新高。現漲5.94%,報53.5港元,暫成交2.4億港元,最新總市值571億港元。平安好醫生近期獲北水青睞,港股通持倉比例持續增加。此外,平安好醫生用户數已突破3億,市民上網看病的習慣日漸養成,醫生職業也進入了全新語境下的“醫生2.0”時代。麥格理本月初表示,平安好醫生在中國的在線醫療診療服務中排名第一,憑藉其卓越的用户體驗,月活躍用户數超過其他前10名同業的總和。給予平安好醫生“優於大市”的評級,將其目標價定為65港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.